The trial achieved both its Most important endpoints, with semaglutide 2.four mg demonstrating statistically major and top-quality improvements in liver fibrosis without having worsening of steatohepatitis, and resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH when compared to placebo.oneThe next really se